• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Serologic Survey of Pandemic Influenza A (H1N1 2009) in Beijing, China

tetano

Editor, Senior Moderator
Prev Med. 2010 Oct 31. [Epub ahead of print]
Serologic Survey of Pandemic Influenza A (H1N1 2009) in Beijing, China.

Tian LL, Shi WX, Ying-Deng, Pang XH, Peng-Yang, Fang-Huang, Cui SJ, Xin-Zhang, Zhang DT, Wang QY.
Abstract

OBJECTIVE: To examine the frequency and distribution of antibodies against pandemic influenza A (H1N1 2009) [H1N1] in populations in Beijing and elucidate influencing factors.

METHODS: In January 2010, a randomized serologic survey of pandemic H1N1 was carried out. 6 districts were randomly selected with a total of 4601 participants involved in the survey have their antibody level tested by haemagglutination inhibition (HI) assay.

RESULTS: Among the 4601 participants, the overall seropositive rate for pandemic H1N1 antibodies was 31.7%. The seropositivity prevalence in participants who received the pandemic H1N1 vaccination was 60.9%. Only 53.1% of the pandemic H1N1seropositive individuals who had not received the vaccination experienced respiratory tract infection symptoms. Multivariate logistic regression revealed that factors such as age, occupation, dwelling type, whether the participant's family included students in school, and the vaccination history with pandemic H1N1 were associated with antibody titers(p<0.05).

CONCLUSIONS: Our data indicated that almost 30.0% of the residents had appropriate antibody titers against pandemic H1N1 in Beijing, and these titers may provide an immune barrier.
Copyright ? 2010. Published by Elsevier Inc.

PMID: 21047527 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/21047527
 
Back
Top Bottom